Several genes (CCK, SLCO1A2, UGGT2) were identified as targets of drugs (diazoxide, nadolol, hydrochlorothiazide) used to treat hypertension, suggesting opportunities for drug repositioning and risk factor prevention. This evidence concerns the gene CCK and hypertensive disorder.